^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1945 Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Published date:
11/04/2020
Excerpt:
In 10 pts who were refractory to or relapsed after ‘triplet’ therapy, the most frequent mutations at screening were DNMT3A (4), IDH1/2 (4), and N/KRAS (3).
Secondary therapy:
decitabine
